Viatris Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VTRS, updated each market day.
VTRS AI Sentiment
AI sees no strong directional signal for Viatris Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Viatris Inc. Common Stock
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Sector
Exchange
Market Cap
$19,675,361,500
Cap Tier
Employees
30,000
Headquarters
CANONSBURG, PA
Listed Since
Feb. 23, 1973
Website
VTRS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VTRS Volatility
Viatris Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
